TOP HEADLINES

Featured Story

  • Pfizer, 23andMe start building 5,000-person lupus database

    Pfizer and 23andMe have begun enrolling people in their lupus study. The partners aim to recruit 5,000 people into the study of the genetics of lupus over the next 12 months, in part by asking existing 23andMe customers to participate.

Genomics England searches for tumor sample processing improvements to boost data quality

Genomics England has run into teething problems in the first few months of its massive genome sequencing initiative. About half of tumor samples sequenced to date have yielded substandard data, a shortcoming Genomics England is trying to overcome by trialing new processes and working with hospitals to incorporate the practices into their day-to-day tasks.

Trialbee raises $5M to mount U.S. expansion of online trial enrollment business

Trialbee has raised $5 million to expand its clinical trial recruitment business in the U.S.

Gentleman aims to use 23andMe's R&D blank slate to tip in vivo-in silico testing balance

Robert Gentleman has shared details of what he wants to achieve as 23andMe's VP of computational biology. And the ex-Genentech bioinformatics chief is looking to turn 23andMe's inexperience in drug discovery into a strength, notably by relying more on computational methods to generate data in early-stage tests.

Celgene taps Cypher Genomics to spot biomarkers in data sets

Celgene has struck a deal with Cypher Genomics to boost its ability to find biomarkers. The agreement gives Celgene access to Cypher's Coral technology, a resource it thinks could help it identify the signatures of novel biomarkers in genomic data.

Hedge fund aims algorithms at pharma patents to sink stocks

Hedge fund manager Kyle Bass has outlined how he picks pharma patents to challenge for his new money-spinning project. The project is underpinned by two emerging assets commonly thought of as a potential boon for drug developers: large data sets and algorithms with which to interrogate them.

MORE NEWS

From Our Sister Sites

FierceBiotech

Bavarian Nordic has downplayed its interest in becoming the latest European biotech to be scooped up by a deep-pocketed suitor. The vaccine player has regained some of its luster over the past year through deals with Bristol-Myers Squibb and Johnson & Johnson, but has no desire to cash in on its moment in the limelight.

FierceCRO

U.K. CRO Ergomed is expanding its share of the postmarketing services business, buying a medical information firm that fields patient queries for drug companies.